MEDsan Pharmaceutical was established in 1988 in the city of Ankara in Turkey and it has been managed by two pharmacists – Ahmet Rustu Olcay and H Huseyin Dokmeci – since 1990.
Over the past 30 years, MEDsan's main market strategy has been importing and selling products which do not have a presence in the prescribed pharmaceutical market in Turkey.
Its new NETDA production plant – located in Nantong city, in East China's Jiangsu province – cost 500 million yuan ($78.43 million) and is on a site covering a total area of about 2 hectares, with a construction area of about 21,000 square meters.
It will be engaged in the research and development and production of COVID-19 detection reagents.